ArticleJournal of managed care & specialty pharmacy2025
Mind over migraine: Disease burden, innovative therapies, and managed care trends in treating migraine disease.
Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative Migraine Therapy: From Current Concepts to Future Directions-A Plastic Surgeon's Perspective.Medicina (Kaunas, Lithuania) · 2025Review
- Mind over migraine: Disease burden, innovative therapies, and managed care trends in treating migraine disease.Journal of managed care & specialty pharmacy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migraine is a genetically influenced complex neurological disease characterized by attacks of moderate to severe headaches and a variety of concomitant symptoms. Migraine disease can significantly impact individuals' daily activities and quality of life. It is a major cause of disability and loss of productivity, which can be exacerbated by migraine-related stigma. Recent advances in migraine treatment and ongoing research may offer additional options for patients; however, treatment barriers still exist, resulting in underdiagnosis and undertreatment of migraine disease, especially in some minority and vulnerable groups. Primary care and emergency department providers are often the first point of contact for patients with migraine disease, so there is opportunity for them to assist in addressing these barriers, particularly with strategies to make care more patient-centered. Managed care organizations can also play a role in overcoming these barriers and supporting equitable access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.